← Back to Screener
Cardiff Oncology, Inc. Common Stock (CRDF)
Price$1.50
Value ScoreD
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-42.14%
Price vs S&P 500 (4W)-8.53%
VGM Score29.71
Market Capitalization$102.55M
All Metrics
Book Value / Share (Quarterly)$0.51
P/TBV (Annual)0.50x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.99%
Cash Flow / Share (Quarterly)$-0.55
Price vs S&P 500 (YTD)-54.78%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-8526.10%
EPS (TTM)$-0.67
10-Day Avg Trading Volume2.15M
EPS Excl Extra (TTM)$-0.67
Revenue Growth (5Y)9.89%
EPS (Annual)$-0.69
ROI (Annual)-101.02%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-8131.43%
Cash / Share (Quarterly)$0.67
Revenue Growth QoQ (YoY)-62.39%
ROA (Last FY)-74.09%
Revenue Growth TTM (YoY)-10.71%
EBITD / Share (TTM)$-0.70
ROE (5Y Avg)-54.35%
Operating Margin (TTM)-9033.90%
Cash Flow / Share (Annual)$-0.56
P/B Ratio2.95x
P/B Ratio (Quarterly)3.19x
Net Income / Employee (Annual)$-1,479,100
EV / Revenue (TTM)179.07x
Net Interest Coverage (TTM)-100.63x
ROA (TTM)-71.45%
EPS Incl Extra (Annual)$-0.69
Current Ratio (Annual)3.67x
Quick Ratio (Quarterly)3.20x
3-Month Avg Trading Volume1.05M
52-Week Price Return-58.56%
Revenue / Employee (TTM)$16,900
Tangible BV / Share (Quarterly)$1.74
P/S Ratio (Annual)172.94x
Asset Turnover (Annual)0.01x
52-Week High$4.56
Operating Margin (5Y Avg)-8586.53%
EPS Excl Extra (Annual)$-0.69
CapEx CAGR (5Y)-26.84%
Tangible BV CAGR (5Y)74.85%
26-Week Price Return-34.21%
Quick Ratio (Annual)3.59x
13-Week Price Return-19.79%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.27x
Enterprise Value$94.01M
Revenue / Share Growth (5Y)-12.85%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-28.19%
Revenue / Employee (Annual)$19,100
Pretax Margin (Annual)-7732.04%
Cash / Share (Annual)$0.85
3-Month Return Std Dev76.70%
Gross Margin (5Y Avg)-134.65%
Net Income / Employee (TTM)$-1,443,900
ROE (Last FY)-101.02%
Net Interest Coverage (Annual)-65.17x
EPS Basic Excl Extra (Annual)$-0.69
Receivables Turnover (TTM)1.76x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.67
Receivables Turnover (Annual)0.72x
ROI (TTM)-95.50%
P/S Ratio (TTM)195.34x
Pretax Margin (5Y Avg)-8131.43%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$2.38
Price vs S&P 500 (52W)-82.93%
Year-to-Date Return-46.62%
5-Day Price Return1.35%
EPS Normalized (Annual)$-0.69
ROA (5Y Avg)-44.76%
Net Profit Margin (Annual)-7732.04%
Month-to-Date Return-21.05%
Cash Flow / Share (TTM)$-0.91
EBITD / Share (Annual)$-0.73
Operating Margin (Annual)-8256.32%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-54.35%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-0.67
P/TBV (Quarterly)0.68x
P/B Ratio (Annual)4.17x
Pretax Margin (TTM)-8526.10%
Book Value / Share (Annual)$0.66
Price vs S&P 500 (13W)-28.04%
Beta1.43x
Revenue / Share (TTM)$0.01
ROE (TTM)-95.50%
52-Week Low$1.35
vGradeD
gGradeD
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.18est. -0.14
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.07
4.07
4.07
4.07
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CRDFCardiff Oncology, Inc. Common Stock | D | D | D | $1.50 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor designed to enhance standard cancer treatments through combination therapy. The company is advancing clinical trials in RAS-mutated metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, triple negative breast cancer, and chronic myelomonocytic leukemia.